BIYKEM BOZKURT to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications BIYKEM BOZKURT has written about Diabetes Mellitus, Type 2.
Connection Strength
0.470
-
Baseline characteristics in the SYNCHRONIZE?-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes Obes Metab. 2026 Feb; 28(2):1490-1498.
Score: 0.112
-
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
Score: 0.094
-
Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes Obes Metab. 2022 11; 24(11):2071-2080.
Score: 0.089
-
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
Score: 0.085
-
Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009 Jul 28; 54(5):422-8.
Score: 0.036
-
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE?-1). Diabetes Obes Metab. 2026 Jan; 28(1):337-346.
Score: 0.028
-
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Metabolism. 2024 10; 159:155931.
Score: 0.025